BR9912899A - Peptìdeos derivados do tnf para uso no tratamento de edema - Google Patents

Peptìdeos derivados do tnf para uso no tratamento de edema

Info

Publication number
BR9912899A
BR9912899A BR9912899-3A BR9912899A BR9912899A BR 9912899 A BR9912899 A BR 9912899A BR 9912899 A BR9912899 A BR 9912899A BR 9912899 A BR9912899 A BR 9912899A
Authority
BR
Brazil
Prior art keywords
edema
tnf
relates
present
treatment
Prior art date
Application number
BR9912899-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Rudolf Lucas
Patrick De Baetselier
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR9912899A publication Critical patent/BR9912899A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9912899-3A 1998-08-14 1999-08-10 Peptìdeos derivados do tnf para uso no tratamento de edema BR9912899A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (1)

Publication Number Publication Date
BR9912899A true BR9912899A (pt) 2001-05-08

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912899-3A BR9912899A (pt) 1998-08-14 1999-08-10 Peptìdeos derivados do tnf para uso no tratamento de edema

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1105152A1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CN105188735A (zh) * 2013-04-23 2015-12-23 阿佩普蒂科研究和开发有限责任公司 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途
CA2940351A1 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére

Also Published As

Publication number Publication date
CZ2001538A3 (cs) 2001-08-15
HK1051805A1 (en) 2003-08-22
CN1181886C (zh) 2004-12-29
EP1105152A1 (en) 2001-06-13
EP1264599A1 (en) 2002-12-11
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
DK1264599T3 (da) 2008-02-04
WO2000009149A1 (en) 2000-02-24
DE69937206D1 (de) 2007-11-08
IL141064A (en) 2009-09-01
EP1247531B1 (en) 2008-05-14
PL345997A1 (en) 2002-01-14
ATE374039T1 (de) 2007-10-15
US7258861B2 (en) 2007-08-21
ZA200100656B (en) 2005-06-29
HU227661B1 (hu) 2011-10-28
ATE395072T1 (de) 2008-05-15
JP4542266B2 (ja) 2010-09-08
ES2296872T3 (es) 2008-05-01
EP1264599B1 (en) 2007-09-26
CA2334941C (en) 2011-08-09
PL203706B1 (pl) 2009-11-30
NZ509604A (en) 2003-05-30
JP2002522508A (ja) 2002-07-23
AU5620999A (en) 2000-03-06
TR200100338T2 (tr) 2001-12-21
EP1247531A3 (en) 2002-12-18
IL141064A0 (en) 2002-02-10
CZ302862B6 (cs) 2011-12-21
DE69937206T2 (de) 2008-06-19
EP1247531A2 (en) 2002-10-09
DE69938743D1 (de) 2008-06-26
CA2334941A1 (en) 2000-02-24
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
AU764992B2 (en) 2003-09-04
PT1264599E (pt) 2008-01-07
CN1312724A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
BRPI0011152B8 (pt) peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0206985A (pt) Anticorpos modificados e métodos de uso
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
DK0592480T3 (da) Anvendelse af papillomavirus L2-protein til terapeutisk behandling af papillomavirustumorer eller -læsioner
AU6473999A (en) Protein material for slow digestion and its use
IL141064A (en) Use of tnf-derived peptides for the manufacture of a medicament for treating oedema
CY1115918T1 (el) Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
ES2143780T3 (es) Compuestos que enlazan las quinasas ciclinodependientes.
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
BR112021023957A2 (pt) Peptídeos
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
AU2002309121A1 (en) Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
BR0211245A (pt) Alimento contendo proteìna compreendendo uma enzima de ligação cruzada e um hidrocolóide
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
BR9805538A (pt) Ferro-succinilcaseìna, processo para a preparação de ferro-succinilcaseìna, complexo férrico succinilado de caseìna alimentar, composição farmacêutica para o tratamento terapêutico de estados patológicos derivados de carência de ferro e uso do complexo férrico de caseìna alimentar succinilada.
LT2002051A (en) Mimetic peptides for epitope of apoliprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
NO991653D0 (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
IT1320782B1 (it) Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
PT804182E (pt) Utilizacao de gabapentina para o tratamento da ansiedade e do panico
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
NO951762L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
BR0012704A (pt) Anticorpos antitumor, proteìnas e usos dos mesmos

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: INNOGENETICS N.V. (BE)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020070169733/RJ DE 30/11/2007, APRESENTE O DOCUMENTO DE CESSAO COM A LEGALIZACAO CONSULAR.

B25A Requested transfer of rights approved

Owner name: DR. RUDOLF LUCAS (BE)

Free format text: TRANSFERIDO DE: INNOGENETICS N.V.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time